M&A - Enliven Therapeutics, Inc.

Form Type: 10-K

Filing Date: 2025-03-13

Corporate Action: Merger

Type: Update

Accession Number: 000095017025038758

Filing Summary: Enliven Therapeutics, Inc. reports on its merger with Imara Inc. completed on February 23, 2023. The filing reveals significant details about the company’s operations, including a focus on the development of small molecule therapeutics for oncology. Enliven highlights its lead product candidates, ELVN-001 and ELVN-002, alongside ongoing clinical trials that have shown promising preliminary results. The company discusses market strategies, development goals, and regulatory pathways, demonstrating an emphasis on addressing unmet medical needs in chronic myeloid leukemia (CML). The report also emphasizes the company’s financial position, including shareholder matters and future expectations for drug approvals and operational success. Enliven's plans for the year ahead focus on advancing its clinical pipeline and improving patient outcomes in precision oncology.

Document Link: View Document